HRP20140280T1 - Uporaba 1-fenil-3-dimetilamino-propan spojeva u terapiji neuropatske boli - Google Patents

Uporaba 1-fenil-3-dimetilamino-propan spojeva u terapiji neuropatske boli Download PDF

Info

Publication number
HRP20140280T1
HRP20140280T1 HRP20140280AT HRP20140280T HRP20140280T1 HR P20140280 T1 HRP20140280 T1 HR P20140280T1 HR P20140280A T HRP20140280A T HR P20140280AT HR P20140280 T HRP20140280 T HR P20140280T HR P20140280 T1 HRP20140280 T1 HR P20140280T1
Authority
HR
Croatia
Prior art keywords
dimethylamino
therapy
phenyl
neuropathy pain
propane compounds
Prior art date
Application number
HRP20140280AT
Other languages
English (en)
Croatian (hr)
Inventor
Thomas Christoph
Babette-Yvonne Kögel
Elmar Friderichs
Muriel Meen
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39345501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140280(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of HRP20140280T1 publication Critical patent/HRP20140280T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HRP20140280AT 2007-03-12 2008-03-10 Uporaba 1-fenil-3-dimetilamino-propan spojeva u terapiji neuropatske boli HRP20140280T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007012165A DE102007012165A1 (de) 2007-03-12 2007-03-12 Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
PCT/EP2008/001884 WO2008110323A1 (de) 2007-03-12 2008-03-10 Verwendung von 1-phenyl-3-dimethylamino-propanverbindungen zur therapie des neuropathieschmerzes

Publications (1)

Publication Number Publication Date
HRP20140280T1 true HRP20140280T1 (hr) 2014-04-25

Family

ID=39345501

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140280AT HRP20140280T1 (hr) 2007-03-12 2008-03-10 Uporaba 1-fenil-3-dimetilamino-propan spojeva u terapiji neuropatske boli

Country Status (13)

Country Link
US (2) US20080269326A1 (cg-RX-API-DMAC7.html)
EP (1) EP2117525B1 (cg-RX-API-DMAC7.html)
JP (5) JP2010520907A (cg-RX-API-DMAC7.html)
CA (1) CA2680771C (cg-RX-API-DMAC7.html)
CY (1) CY1115455T1 (cg-RX-API-DMAC7.html)
DE (1) DE102007012165A1 (cg-RX-API-DMAC7.html)
DK (1) DK2117525T3 (cg-RX-API-DMAC7.html)
ES (1) ES2452830T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20140280T1 (cg-RX-API-DMAC7.html)
PL (1) PL2117525T3 (cg-RX-API-DMAC7.html)
PT (1) PT2117525E (cg-RX-API-DMAC7.html)
SI (1) SI2117525T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008110323A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
DK3656765T3 (da) * 2010-07-23 2021-06-14 Gruenenthal Gmbh Salte eller co-krystaller af 3-(3-dimethylamin-1-ethyl-2-methyl-propyl)-phenol
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
LT3287123T (lt) * 2011-03-04 2020-06-10 Grünenthal GmbH Vandeninė farmacinė tapentadolio kompozicija, skirta gerti
BR112013022556A8 (pt) * 2011-03-04 2018-01-16 Gruenenthal Gmbh composição farmacêutica aquosa semissólida contendo tapentadol, seu uso e uso de tapentadol
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
EP2680833B1 (en) 2011-03-04 2016-03-02 Grünenthal GmbH Parenteral administration of tapentadol
WO2012136351A1 (en) 2011-04-05 2012-10-11 Grünenthal GmbH Tapentadol for treating pain associated with trigeminal neuralgia
PT2694049T (pt) 2011-04-05 2019-02-06 Gruenenthal Gmbh Tapentadol para prevenir a cronicidade da dor
ES2646363T3 (es) 2011-04-29 2017-12-13 Grünenthal GmbH Tapentadol para la prevención y el tratamiento de la depresión y la ansiedad
US8853393B2 (en) 2011-07-29 2014-10-07 Anhui New Star Pharmaceutical Development Co., Ltd. Intermediate for preparing tapentadol or analogues thereof
WO2013017233A1 (en) * 2011-07-29 2013-02-07 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
CN103159633B (zh) * 2012-07-06 2015-08-12 江苏恩华药业股份有限公司 他喷他多的制备方法及用于制备他喷他多的化合物
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EA036258B1 (ru) 2015-03-27 2020-10-20 Грюненталь Гмбх Стабильный препарат для парентерального введения тапентадола
WO2018055070A1 (en) 2016-09-23 2018-03-29 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
ES2819854T3 (es) * 2002-11-22 2021-04-19 Gruenenthal Gmbh Uso de (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol para tratar el dolor inflamatorio
JP5496653B2 (ja) * 2006-04-28 2014-05-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）−フェノール、およびパラセタモールを含む医薬の組合せ

Also Published As

Publication number Publication date
CA2680771A1 (en) 2008-09-18
PT2117525E (pt) 2014-02-14
PL2117525T3 (pl) 2014-05-30
JP2010520907A (ja) 2010-06-17
WO2008110323A1 (de) 2008-09-18
ES2452830T3 (es) 2014-04-02
EP2117525A1 (de) 2009-11-18
JP2016056188A (ja) 2016-04-21
DK2117525T3 (da) 2014-02-03
JP6745959B2 (ja) 2020-08-26
US8536130B2 (en) 2013-09-17
CA2680771C (en) 2015-11-17
JP2013256540A (ja) 2013-12-26
CY1115455T1 (el) 2017-01-04
SI2117525T1 (sl) 2014-03-31
JP6081337B2 (ja) 2017-02-15
JP2018030886A (ja) 2018-03-01
EP2117525B1 (de) 2013-12-25
JP2019196405A (ja) 2019-11-14
US20100311842A1 (en) 2010-12-09
US20080269326A1 (en) 2008-10-30
DE102007012165A1 (de) 2008-09-18

Similar Documents

Publication Publication Date Title
HRP20140280T1 (hr) Uporaba 1-fenil-3-dimetilamino-propan spojeva u terapiji neuropatske boli
WO2008096775A1 (ja) 疼痛疾患治療剤
MX2010013766A (es) Rasagilina para modificacion de enfermedad de parkinson.
JP2015515475A5 (cg-RX-API-DMAC7.html)
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2009127974A3 (ko) 심혈관계 질환 치료용 약제학적 제제
BRPI0818687A2 (pt) composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença.
CL2012003171A1 (es) Compuestos derivados de ciclohexilamina, con actividad dual agonista con el receptor m3 muscarinico y agonista con el receptor b2 adrenérgicos; composición farmacéutica que comprende un compuesto; combinación; farmaceutica; y su uso de un compuesto en la preparacion de medicamento de enfermedades respiratorias.
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
JO3272B1 (ar) مستحضر صلب يشمل ألوجليبتين وميتفورمين هيدروكلوريد
MX2012009079A (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2011159100A2 (ko) 항암 활성을 나타내는 약제학적 조성물
CA2736751A1 (en) Salts of n-[6-(cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
WO2007078895A3 (en) Modified release formulations of tramadol and uses thereof
MY163762A (en) Therapeutic agent for chronic renal failure
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2007145863A3 (en) Sustained release formulation of naltrexone
WO2008048648A3 (en) Cb1-modulating compounds and their use
ZA201007391B (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potassium in the blood
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2007098967A3 (en) Imidazole compounds having pharmaceutical activity towards the sigma receptor
WO2006124413A3 (en) Methods for treating drug resistant cancer
HRP20200691T1 (hr) Pedijatrijska formulacija
JP6116678B2 (ja) （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよびＮＳＡＲを含む医薬組成物